Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Daratumumab
- DRUG Pomalidomide
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Aventura — Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs — Coral Springs
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood
- Griffin Cancer Research Building (GCRB) — Miami
- Sylvester Comprehensive Cancer Center — Miami
- University of Miami Hospital and Clinics — Miami
- Sylvester Comprehensive Cancer Center - Kendall — Miami
- Sylvester Comprehensive Cancer Center - Plantation — Plantation
California
- Clovis Community Medical Center — Clovis
- Community Cancer Institute — Clovis
- University of California San Francisco — Fresno
- Community Regional Medical Center — Fresno
Colorado
- UCHealth Poudre Valley Hospital — Fort Collins
- UCHealth Harmony — Fort Collins
- UCHealth Greeley Hospital — Greeley
- UCHealth - Medical Center of the Rockies — Loveland
Louisiana
- East Jefferson General Hospital — Metairie
New Jersey
- MSK Basking Ridge — Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 944 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020236
The ClinicalTrials.gov registry entry for NCT05020236 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 944 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions — of which Dexamethasone is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05020236 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Florida, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05020236 about?
NCT05020236 is a clinical study titled "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments". The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of el...
What is the current status of trial NCT05020236?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 944 participants. The study started on 2021-10-04. Estimated completion is 2027-05-31.
What conditions does trial NCT05020236 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05020236?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05020236?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05020236 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.